Silence Therapeutics Makes Non-Exec Changes
This article was originally published in Scrip
Silence Therapeutics Plc. has appointed Stuart Collinson non-executive director of the company and Simon Sturge, current non-executive director, has resigned because of other business commitments – effective immediately. Sturge has also resigned from the company's board and Collinson will chair the remuneration committee. Collinson is a partner of Forward Ventures, a biopharmaceutical venture capital fund, chair and CEO of Tioga Pharmaceuticals, Inc., director of Arcturus Therapeutics, Inc., and Essentialis. Previously, Collinson was chair, CEO and president of Aurora Bioscience Corp., which was acquired by Vertex Pharmaceuticals. Inc., after which he became director of the company. He has also held senior management positions at GlaxoWellcome Plc. (now GlaxoSmithKline Plc.) and Baxter International.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.